

# Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying Direct-Acting Antiviral Scale-up Trial

Clinical Infectious Diseases

73, e2164-e2172

DOI: [10.1093/cid/ciaa1500](https://doi.org/10.1093/cid/ciaa1500)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2172-e2174.	5.8	6
2	HCV Elimination in Australia. , 2021, , 213-227.		0
3	Brief Report: Low Incidence of Hepatitis C Among a Cohort of HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP) in Melbourne, Australia, and the Contribution of Sexual Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1011-1015.	2.1	4
4	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <i>Gut</i> , 2021, 70, 2349-2358.	12.1	25
5	Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 18, 100316.	2.9	4
6	Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020. <i>International Journal of Drug Policy</i> , 2022, 103, 103655.	3.3	8
7	Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. <i>Epidemiology and Infection</i> , 2022, 150, e7.	2.1	1
8	Hepatitis C microelimination among people living with HIV in Taiwan. <i>Emerging Microbes and Infections</i> , 2022, 11, 1664-1671.	6.5	6
9	Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. <i>AIDS and Behavior</i> , 2023, 27, 119-133.	2.7	5
10	Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	10
11	Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort. <i>Health Science Reports</i> , 2022, 5, .	1.5	0
12	Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. <i>Harm Reduction Journal</i> , 2022, 19, .	3.2	1
13	Risky sexual practices and hepatitis C viremia among HIV-positive men who have sex with men in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 566-574.	3.1	5
14	Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019. <i>EClinicalMedicine</i> , 2023, 56, 101810.	7.1	6
15	Does sexuality matter? A cross-sectional study of drug use, social injecting, and access to injection-specific care among men who inject drugs in Melbourne, Australia. <i>Harm Reduction Journal</i> , 2023, 20, .	3.2	3
16	Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis. <i>Hepatology Communications</i> , 2023, 7, .	4.3	1
17	Pre-Emptying Stigma and Complicating Trauma: Narratives of Gay and Bisexual Men who Inject Drugs in Australia. <i>Qualitative Health Research</i> , 0, , 104973232311737.	2.1	0
18	Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut. <i>Public Health Reports</i> , 2024, 139, 208-217.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods. <i>Health Promotion Practice</i> , 2023, 24, 1039-1049.	1.6	3
20	Hepatitis C Virus—HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics. <i>Public Health Reports</i> , 0, , .	2.5	0
21	HCV Microelimination for High-risk Special Populations. <i>Journal of Infectious Diseases</i> , 2023, 228, S168-S179.	4.0	4
22	Incidence and Prevalence of Hepatitis C Virus Among HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP): A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	3
23	Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2023, , .	0.5	0
24	Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis. <i>Liver International</i> , 2023, 43, 2625-2644.	3.9	0
25	Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. <i>Enfermedades Infecciosas Y Microbiología Clínica (English)</i> <a href="#">Tj ETQq0 0 0 r0BT /Overlock 10 Tf 5</a>	0.5	0
26	Low Hepatitis C Virus Prevalence among Men Who Have Sex with Men Attending Public Health Services in The Netherlands. <i>Viruses</i> , 2023, 15, 2317.	3.3	0
27	Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC). <i>International Journal of Epidemiology</i> , 2024, 53, .	1.9	0
29	Hepatitis C virus reinfection incidence among gay and bisexual men with <scp>HIV</scp> in Australia from 2016 to 2020. <i>Liver International</i> , 2024, 44, 1024-1031.	3.9	0
30	Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example. <i>Infectious Diseases and Therapy</i> , 2024, 13, 549-564.	4.0	0